Would you consider a JAK inhibitor as first-line therapy for chronic eosinophilic leukemia (CEL) with an activating STAT mutation in the absence of a targetable kinase fusion?

What would you use for first-line therapy for CEL with an activating STAT mutation and no targetable kinase fusion in a patient who is not a candidate for HSCT?

• JAK inhibitor (e.g., ruxolitinib)
• Hydroxyurea
• Interferon-α
• Hypomethylating agent
• Other